Key Highlights

  • Microbot Medical CEO Harel Gadot will join a neurovascular robotics discussion at the Society of Robotic Surgery 2026 event.
  • The panel will focus on developments in robotic-assisted endovascular and neurovascular technologies.
  • The company continues to advance its robotic solutions for minimally invasive medical procedures.
  • The event provides an opportunity to engage with industry leaders and stakeholders in robotic surgery.

Microbot Medical is set to engage with the medical and investment communities at an upcoming industry event, where CEO Harel Gadot will participate in a discussion on neurovascular robotics. The session, part of the Society of Robotic Surgery 2026 program, offers a platform for the company to share insights on the evolving environment of robotic-assisted endovascular procedures. As the medical device sector increasingly adopts robotic technologies to improve procedural precision and patient outcomes, such forums play a key role in shaping industry trends and fostering collaboration.

CEO to Join Neurovascular Robotics Discussion

Harel Gadot, who leads Microbot Medical as CEO, President, and Chairman, will take part in a panel focused on neurovascular robotics at the Society of Robotic Surgery event. The discussion, scheduled for July 21, 2026, will bring together experts in the field to examine the latest advancements in robotic technologies for vascular and neurological applications. Gadot’s participation underscores the company’s commitment to innovation in minimally invasive medical solutions and its role in the broader adoption of robotic systems in healthcare.

Advancing Robotic Solutions in Endovascular Procedures

Microbot Medical has been developing robotic technologies designed to enhance the safety and efficiency of endovascular interventions. The company’s efforts align with a growing trend in the medical device industry, where robotic assistance is increasingly integrated into complex procedures to improve clinical outcomes. As healthcare providers seek to expand the use of minimally invasive techniques, robotic systems are becoming a critical component in addressing the technical challenges associated with these procedures.

Microbot Medical’s work in this area reflects its focus on delivering solutions that support clinicians in delivering high-quality care.

Industry Engagement and Market Dynamics

The Society of Robotic Surgery event provides an important venue for companies like Microbot Medical to connect with surgeons, researchers, and industry stakeholders. These interactions are essential for driving the adoption of new technologies and fostering partnerships that can accelerate innovation. While the medical device sector continues to face challenges related to commercialization and market acceptance, events like this offer opportunities to demonstrate the value of emerging solutions and address questions from the investment community.

Looking Ahead to the SRS 2026 Discussion

The upcoming panel discussion at the Society of Robotic Surgery event will serve as a key moment for Microbot Medical to highlight its progress in robotic-assisted endovascular technologies. As the company continues to refine its offerings and expand its clinical applications, industry engagement remains a priority. The insights shared during the session may provide valuable context for stakeholders evaluating the potential of robotic systems in transforming vascular and neurovascular care.

Based on the company’s press release issued July 21, 2026 [EX-99.1].

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.